JP2024516825A5 - - Google Patents
Info
- Publication number
- JP2024516825A5 JP2024516825A5 JP2023566472A JP2023566472A JP2024516825A5 JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5 JP 2023566472 A JP2023566472 A JP 2023566472A JP 2023566472 A JP2023566472 A JP 2023566472A JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical product
- pharmaceutically acceptable
- acceptable salt
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181640P | 2021-04-29 | 2021-04-29 | |
| US63/181,640 | 2021-04-29 | ||
| PCT/US2022/071967 WO2022232808A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516825A JP2024516825A (ja) | 2024-04-17 |
| JP2024516825A5 true JP2024516825A5 (cg-RX-API-DMAC7.html) | 2025-05-09 |
Family
ID=81749580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566472A Pending JP2024516825A (ja) | 2021-04-29 | 2022-04-28 | トポイソメラーゼi阻害剤のペプチドコンジュゲートの投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226308A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4329817A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516825A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019097A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117897175A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022267389A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218253A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023003187A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308052A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012779A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202308696A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232808A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| CA3032186C (en) | 2010-07-13 | 2022-04-26 | Council on Postsecondary Education, State of Rhode Island and Providence Plantations | Environmentally sensitive composition comprising a ph triggered peptide and uses thereof |
| SG10201913073YA (en) * | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| AU2019205325A1 (en) | 2018-01-05 | 2020-08-13 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US20210106648A1 (en) * | 2019-10-11 | 2021-04-15 | TOBEBIO Novel Drug Laboratory Co., Ltd. | Synergistic combination of chemotherapy and peptide for treating cancer |
-
2022
- 2022-04-28 JP JP2023566472A patent/JP2024516825A/ja active Pending
- 2022-04-28 CA CA3218253A patent/CA3218253A1/en active Pending
- 2022-04-28 MX MX2023012779A patent/MX2023012779A/es unknown
- 2022-04-28 AU AU2022267389A patent/AU2022267389A1/en active Pending
- 2022-04-28 EP EP22724607.1A patent/EP4329817A1/en active Pending
- 2022-04-28 TW TW111116202A patent/TW202308696A/zh unknown
- 2022-04-28 KR KR1020237040934A patent/KR20240019097A/ko active Pending
- 2022-04-28 US US18/288,650 patent/US20240226308A1/en active Pending
- 2022-04-28 CN CN202280044027.3A patent/CN117897175A/zh active Pending
- 2022-04-28 WO PCT/US2022/071967 patent/WO2022232808A1/en not_active Ceased
- 2022-04-28 IL IL308052A patent/IL308052A/en unknown
-
2023
- 2023-10-25 CL CL2023003187A patent/CL2023003187A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510725A5 (cg-RX-API-DMAC7.html) | ||
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| JP5579715B2 (ja) | cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2018528185A5 (cg-RX-API-DMAC7.html) | ||
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN117157106A (zh) | 药物在治疗肿瘤疾病中的应用 | |
| JP2008540364A5 (cg-RX-API-DMAC7.html) | ||
| CN121001749A (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| Fukuoka et al. | Clinical studies of irinotecan alone and in combination with cisplatin | |
| JP2023546316A5 (cg-RX-API-DMAC7.html) | ||
| EP1711188B1 (en) | Anti-cancer therapies | |
| JP5881782B2 (ja) | 医薬組成物又は組合せ剤 | |
| CN105263499B (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| EP2117539B1 (en) | A method of administering an antitumor compound | |
| JP7311177B2 (ja) | A-NOR-5αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2023550043A5 (cg-RX-API-DMAC7.html) | ||
| AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| CN107519171A (zh) | 洛匹那韦减轻伊立替康毒性的医药新用途 | |
| CN1774249A (zh) | 伊立替康在治疗耐受性乳腺癌中的应用 | |
| HK1213475B (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy | |
| CN121127270A (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| JP2023514742A5 (cg-RX-API-DMAC7.html) | ||
| HK1087011A (en) | Use of irinotecan for treatment of resistant breast cancer |